5 years ago

Gamma-glutamyltransferase and cardiovascular mortality in Korean adults: A cohort study

Insufficient evidence has been reported on the associations between gamma-glutamyltransferase (GGT) and cardiovascular disease (CVD) mortality from studies with an adequate number of participants. Methods 512,990 Korean adults who participated in routine health examinations during the period 2002–2003 were followed up until 2013. Hazard ratios (HRs) were calculated after adjusting for potential confounders. Results Each 1-unit higher natural-log-transformed GGT (LogeGGT) level was associated with approximately 30–50% higher mortality risk of CVD (HR = 1.31): hypertensive diseases (HR = 1.31), ischemic heart diseases (IHD, HR = 1.29), total stroke (HR = 1.29), acute myocardial infarction (HR = 1.30), chronic IHD (HR = 1.27), heart failure (HR = 1.48), hemorrhagic stroke (HR = 1.42), and ischemic stroke (HR = 1.27). The associations with CVD mortality did not vary by sex, or alcohol use, whereas they were stronger in younger (<60 years), non-hypertensive (systolic blood pressure [SBP] <140 mmHg), physically more active, normal-weight (body mass index<25 kg/m2), and normocholesterolemic (total cholesterol <200 mg/dL) adults than in their respective counterparts. Adding LogeGGT to prediction models for CVD mortality increased AUC value (0.0020, p < 0.001), especially in persons aged <60 years (0.0055), with SBP <140 mmHg (0.0030), and with both age <60 years and SBP <140 mmHg (0.0086). Conclusions Higher GGT significantly increased the risk of mortality due to CVD and its subtypes. The relative risks were greater in subjects with younger age, no hypertension, more physical activity, normal weight, and normocholesterolemia than in their respective counterparts. In the general population, adding GGT to conventional CVD risk factors may improve the prediction of CVD mortality, especially in subjects younger than 60 years and in those without hypertension.

Publisher URL: www.sciencedirect.com/science

DOI: S0021915017312509

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.